Current Eye Research · 2008 · 92 citations · 41 references
Life SciencesCell BiologyPharmacologyApoptosisDrug DeliveryToxicokineticsApoptosis PharmacologyApoptotic SignalingCellular ToxicologyCytotoxicity EvaluationAnti-apoptotic AgentsAntiglaucoma TherapyMembrane Integrity AssaysMembrane Integrity TestingPreservative-free Topical FormulationsPro-apoptotic AgentsProstaglandin Analog TherapyProstaglandin Analogues
PURPOSE: This study compared the toxicity profiles of three antiglaucoma prostaglandin F2alpha analogs, latanoprost, travoprost, and bimatoprost which contain benzalkonium chloride (BAK), with tafluprost, a new preservative-free prostaglandin analog. METHODS: IOBA-NHC cells were exposed to BAK-containing prostanoid solutions, their respective BAK concentrations, and preservative-free tafluprost solution for 30 min. Membrane integrity, apoptosis, oxidative stress, and cells morphology were evaluated. RESULTS: Preservative-free tafluprost resulted in significantly higher membrane integrity and lower pro-apoptotic and pro-oxidative effects than preservative-containing prostaglandin analog preparations. CONCLUSIONS: These results suggest that tafluprost, a new preservative-free prostaglandin analog, has very low or no pro-apoptotic, pro-necrotic, or pro-oxidative effects in vitro compared to preservative-containing formulations.
41
Adverse Effects of Topical Antiglaucoma Medication
David C. Broadway · Archives of Ophthalmology · 1994 · 525 citations
Medicine, Ophthalmology, Surgery +17
Ocular surface inflammatory changes induced by topical antiglaucoma drugs
Christophe Baudouin, Pierre‐Jean Pisella, Kathleen Fillacier et al. · Ophthalmology · 1999 · 393 citations